登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，4月8日，Tuberculosis and HIV responses threatened by COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-09

  • Tuberculosis and HIV responses threatened by COVID-19

    Paul Adepoju

    Published:April 08, 2020DOI:https://doi.org/10.1016/S2352-3018(20)30109-0

    As the first cases of COVID-19 affect Nigeria's health-care workers, will the country's HIV and tuberculosis responses weather the pandemic? Paul Adepoju reports.

    March 24, 2020, was World Tuberculosis Day 2020, but this year tuberculosis was overshadowed by the COVID-19 pandemic. By the end of that week, COVID-19 had already exceeded 600?000 confirmed cases and about 30?000 deaths worldwide. Before the emergence of COVID-19 as a public health emergency of international concern, coinfection with tuberculosis was probably the priority for HIV/AIDS control efforts in Africa.

  • 原文来源：https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30109-0/fulltext
7浏览量
原文链接
相关报告

  • 《LANCET，2月29日，Indian pharma threatened by COVID-19 shutdowns in China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-29
    • Indian pharma threatened by COVID-19 shutdowns in China Patralekha Chatterjee Published:February 29, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30459-1 As factories in China are closed, India is working to maintain supplies of active pharmaceutical ingredients. Patralekha Chatterjee reports from New Delhi. India supplies low-cost generic drugs to millions of people, both within and outside the country. But Indian pharmaceutical companies procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China, the world's leading producer and exporter of APIs by volume. As factories in China are closed to try to stem the coronavirus disease 2019 outbreak, pharmaceutical companies and the Indian Government are becoming concerned over the vulnerability of the Indian pharmaceutical supply chain.
    62浏览量
    原文链接

  • 《LANCET，4月8日，Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-09
    • Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic Bruno H R de Paula Indiara Araújo Lívia Bandeira Nathália M P B Barreto Gary J Doherty Published:April 08, 2020DOI:https://doi.org/10.1016/S1470-2045(20)30226-6 Clinical research has transformed cancer care and is often integrated seamlessly into routine oncology clinics, offering eligible patients additional treatment options or lines of therapy. Typically, and particularly for diseases with poor prognoses or when trials entail biomarker-directed personalised treatment, clinical trial enrolment can be preferred (by both doctors and patients) over standard care.
    91浏览量
    原文链接